leisure time -WSS

leisure time

author：focus 2025-10-01 01:00:26 - browse：3743

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Researchers explore possible ties between long Covid, menopause

focus

WSS

After a drawn out lobbying fight, ARPA

Biogen shutters digital health group, ends Apple study, in cost cutting move

After a drawn out lobbying fight, ARPA

Solve the antibiotic resistance crisis with preventive drugs

FDA gives detailed accounting of AI

Why do women spend more than men on medical expenses?

focus

leisure time

leisure time

The high cost of giving birth even with insurance

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Novavax promises a turnaround & Lilly roils the obesity market

WHO recommends dropping component of many flu vaccines

After affirmative action ruling, medical educators look to 'holistic review'

Would Medicare drug price negotiations stall in a shutdown?

Affirmative action in medical school literally saved lives

Address the ethical violations that led to 'Three Identical Strangers'

Medicare details structure of new drug price negotiation program

Menendez indictment could see pharma lose a key ally

hotspot

FDA gives detailed accounting of AI

Would Medicare drug price negotiations stall in a shutdown?

Did you have Obamacare on your GOP debate bingo card?

First Opinion Podcast: Long Covid needs a new approach

FDA advisers vote against ALS treatment from BrainStorm

Covid vaccines: Private market messier than government rollout

hotspot

Wikipedia

focus

leisure time